Evidence map›Paper›PMID 30864056›Full record

ArticlePaediatric drugs2019

Vancomycin Prescribing and Therapeutic Drug Monitoring in Children With and Without Acute Kidney Injury After Cardiac Arrest.

Julie C Fitzgerald, Nicole R Zane, Adam S Himebauch, Michael D Reedy, Kevin J Downes, Alexis A Topjian, Susan L Furth, Neal J Thomas, Marc H Scheetz, Athena F Zuppa

Open access · greenAbstract read
In one paragraph

Article in Paediatric drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 3 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Julie C FitzgeraldDepartment of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia and The University of Pennsylvania Perelman School of Medicine, 3401 Civic Center Blvd, 6th Floor Wood Building, Room 6117, Philadelphia, PA, 19104, USA. fitzgeraldj@email.chop.edu.ORCID http://orcid.org/0000-0001-9936-9569
Nicole R ZaneCenter for Clinical Pharmacology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Adam S HimebauchDepartment of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia and The University of Pennsylvania Perelman School of Medicine, 3401 Civic Center Blvd, 6th Floor Wood Building, Room 6117, Philadelphia, PA, 19104, USA.
Michael D ReedyDepartment of Pharmacy, Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, USA.
Kevin J DownesCenter for Clinical Pharmacology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Alexis A TopjianDepartment of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia and The University of Pennsylvania Perelman School of Medicine, 3401 Civic Center Blvd, 6th Floor Wood Building, Room 6117, Philadelphia, PA, 19104, USA.
Susan L FurthDepartment of Pediatrics, Children's Hospital of Philadelphia and The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Neal J ThomasDepartment of Pediatrics, Penn State Hershey Children's Hospital, Penn State University College of Medicine, Hershey, PA, USA.
Marc H ScheetzDepartment of Pharmacy Practice, Pharmacometric Center of Excellence, Midwestern University, Downers Grove, IL, USA.
Athena F ZuppaDepartment of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia and The University of Pennsylvania Perelman School of Medicine, 3401 Civic Center Blvd, 6th Floor Wood Building, Room 6117, Philadelphia, PA, 19104, USA.
Children's Hospital of Philadelphia · USAlfred I. duPont Hospital for Children · USMidwestern University · USPenn State Milton S. Hershey Medical Center · US

Funding

Chronic Kidney Disease in Children Study (C-Kid)U01DK066174 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SUSAN L. FURTH · 2003 to 2026
$25.1M
CLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM008562 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI WALTER K KRAFT, Scott A. Waldman · 1995 to 2026
$10.2M
Research Project Core 2P50DK114786 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI Michelle Denburg, SUSAN L. FURTH · 2017 to 2026
$9.6M
IMPACT OF TREATMENT OF MILD SLEEP-DISORDERED BREATHING ON CHILDREN'S HEALTH-CCCU01HL125295 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI FURTH, SUSAN L. · 2015 to 2019
$7.9M
The Child-Centered Outcomes in Practice and Research (COPR) Center of Excellence: Strengthening the Clinical Validity Evidence Base for PROMIS Measures in Chronically Ill ChildrenU19AR069525 · NIAMS · CHILDREN'S HOSP OF PHILADELPHIA · PI FORREST, CHRISTOPHER B · 2015 to 2015
$4.2M
GM-CSF for Immunomodulation Following Trauma (GIFT) TrialR01GM094203 · NIGMS · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI HALL, MARK W · 2011 to 2015
$2.4M
Pediatric Critical Care Research Network at Children's Hospital of PhiladelphiaUG1HD063108 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI BERG, ROBERT ALLEN, ZUPPA, ATHENA F. · 2015 to 2020
$1.7M
1/2 PROSpect: Prone and Oscillation Pediatric Clinical Trial (CCC)UG3HL141736 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CHEIFETZ, IRA M, CURLEY, MARTHA AQ · 2018 to 2018
$1.7M
Optimizing Vancomycin Therapy in ChildrenK23HD091365 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI DOWNES, KEVIN JAMES · 2018 to 2022
$747k
RESTORE resilience in critically ill children - R2R21HD093369 · NICHD · UNIVERSITY OF PENNSYLVANIA · PI CURLEY, MARTHA AQ, KUDCHADKAR, SAPNA R · 2017 to 2018
$506k
Elucidation of an informed drug dosing scheme to minimize kidney injuryR15AI105742 · NIAID · MIDWESTERN UNIVERSITY · PI SCHEETZ, MARC HOWARD · 2014 to 2014
$459k
A Model Based Approach to Individualizing Antimicrobial Dosing in Pediatric SepsisK99HD096123 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI ZANE, NICOLE R · 2018 to 2019
$221k
NHLBI NIH HHS U01 HL125295NHLBI NIH HHS UG3 HL141736NIAID NIH HHS R15 AI105742NIAMS NIH HHS U19 AR069525NICHD NIH HHS K23 HD091365NICHD NIH HHS K99 HD096123NICHD NIH HHS R21 HD093369NICHD NIH HHS UG1 HD063108NIDDK NIH HHS P50 DK114786NIDDK NIH HHS U01 DK066174NIGMS NIH HHS R01 GM094203NIGMS NIH HHS T32 GM008562
6 · The paper itself

Abstract

backgroundAcute kidney injury (AKI) commonly occurs after cardiac arrest. Those subsequently treated with vancomycin are at additional risk for drug-induced kidney injury.

objectiveWe aimed to determine whether opportunities exist for improved drug monitoring after cardiac arrest.

methodsThis was a retrospective cohort study of children aged 30 days-17 years treated after cardiac arrest in an intensive care unit from January 2010 to September 2014 who received vancomycin within 24 h of arrest. Vancomycin dosing and monitoring were compared between those with and without AKI, with AKI defined as pRIFLE (pediatric risk, injury, failure, loss, end-stage renal disease) stage 2-3 AKI at day 5 using Schwartz formula-calculated estimated glomerular filtration rate (eGFR).

resultsOf 43 children, 16 (37%) had AKI at day 5. Age, arrest duration, median time to first vancomycin dose, and the number of doses before and time to first vancomycin concentration measurement were similar between groups. Children with AKI had higher initial vancomycin concentrations than those without AKI (median 16 vs. 7 mg/L; p = 0.003). A concentration was not measured before the second dose in 44% of children with AKI. Initial eGFR predicted day 5 AKI. In children with AKI, the initial eGFR was lower in those with than those without a concentration measurement before the second dose (29 mL/min/1.73 m

conclusionsIn children with AKI after cardiac arrest, decreased vancomycin clearance was evident early, and early monitoring was not performed universally in those with low initial eGFR. Earlier vancomycin therapeutic drug monitoring is indicated in this high-risk population.

Indexed as

Acute Kidney InjuryAdolescentAnti-Bacterial AgentsChildChild, PreschoolDrug MonitoringDrug PrescriptionsFemaleGlomerular Filtration RateHeart ArrestHumansInfantInfant, NewbornMaleRetrospective StudiesRisk FactorsAnti-Bacterial AgentsVancomycin

Identifiers

PMID30864056
PMCPMC6526504
OpenAlexW2922007069

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.